Lerociclib HCl (G1T38) is a novel, selective,differentiated oral CDK4/6 inhibitor with biochemical IC50 values of 1 nM, 2 nM and 28 μnM for CDK4, CDK6 and CDK9 respectively. Lerociclib (G1T38) with potential use in combination with other targeted therapies in certain types of breast and lung cancer.
Lerociclib (Free base) , Bulk in stock, contact us by email for the Bulk quotation.
For research use only. We do not sell to patients.
Name | Lerociclib HCl (G1T38 HCl) |
---|---|
Iupac Chemical Name | 2'-((5-(4-isopropylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one dihydrochloride |
Synonyms | Lerociclib HCl ; G1T38 dihydrochloride ; G1T 38 dihydrochloride |
Molecular Formula | C26H36Cl2N8O |
Molecular Weight | 547.52 |
Smile | O=C1NCC2(N3C1=CC4=CN=C(NC5=NC=C(N6CCN(C(C)C)CC6)C=C5)N=C43)CCCCC2.[H]Cl.[H]Cl |
InChiKey | IUIVDLVJNPANBY-UHFFFAOYSA-N |
InChi | InChI=1S/C26H34N8O.2ClH/c1-18(2)32-10-12-33(13-11-32)20-6-7-22(27-16-20)30-25-28-15-19-14-21-24(35)29-17-26(8-4-3-5-9-26)34(21)23(19)31-25;;/h6-7,14-16,18H,3-5,8-13,17H2,1-2H3,(H,29,35)(H,27,28,30,31);2*1H |
CAS Number | 2097938-59-3 |
Related CAS | 2097938-59-3 (HCl) ;1628256-23-4 (free base) |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | light-yellow solid to off-white solid |
---|---|
Purity | ≧98.0% |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Solubility | Soluble in DMSO |
Handling | Avoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation. |
Shipping Condition | Shipped under ambient temperature |
HS Code | 2933999701 |
Targets | CDK4/6 inhibitor |
---|---|
Mechanism | Lerociclib (G1T38 ) is a novel, selective,differentiated oral CDK4/6 inhibitor with biochemical IC50 values of 1 nM, 2 nM and 28 μnM for CDK4, CDK6 and CDK9 respectively. Lerociclib (G1T38) with potential use in combination with other targeted therapies in certain types of breast and lung cancer. |
Cell study | |
Animal study | |
Clinical study |